United States Biotechnology & Medical Research

VivoSim Labs Inc (VIVS)

Track

Track

VivoSim Labs Inc. recorded one insider purchase during the last ninety days. Chief Commercial Officer Tony Serge Lialin acquired ten thousand shares for 2,804 dollars on August 31, 2026. This activity follows a period where the stock price declined significantly, preceding the upcoming November earnings report.
Ticker: VIVS Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for VivoSim Labs Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Lialin Tony Serge Chief Commercial Officer Officer
Transaction date
Purchase
Price
160.39
Quantity 60,828 -34.8%
Value US$569,548
3.3
Gobel David Non-Executive Director
Transaction date
Sale
Price
207.97
Quantity 4,750 -16.7%
Value US$3,459,936
3.3
Gobel David Director Non-Executive Director
Transaction date
Proposed sale
Price
392.25
Quantity 15,365
Value US$3,933,000
Hughes Steven George Chief Medical Officer Officer
Transaction date
Sale
Price
0.29
Quantity 22,230 -13.8%
Value US$6,431
Presnell Sharon Collins Chief Scientific Officer Officer
Transaction date
Planned sale
Price
1.27
Quantity 40,000 -12.0%
Value US$50,800
Murphy Keith Former affiliate last filing
Transaction date
Purchase
Price
1.49
Quantity 200,500 +3.2%
Value US$299,346
Murphy Keith Former affiliate last filing
Transaction date
Purchase
Price
1.50
Quantity 135,000 +2.2%
Value US$201,960
3.0
Murphy Keith Chairman, CEO and President Executive Director
Transaction date
Planned sale
Price
3.68
Quantity 25,000 -0.4%
Value US$92,035
3.0
Murphy Keith Chairman, CEO and President Executive Director
Transaction date
Planned sale
Price
3.50
Quantity 20,100 -0.3%
Value US$70,440
3.0
Murphy Keith Chairman, CEO and President Executive Director
Transaction date
Planned sale
Price
3.51
Quantity 4,900 -0.1%
Value US$17,215
Murphy Keith Chairman, CEO and President Executive Director
Transaction date
Planned sale
Price
3.72
Quantity 50,000 -0.8%
Value US$185,955
David Eric CSO & EVP Pre-Clinical Dev Officer
Transaction date
Planned sale
Price
4.55
Quantity 20,000 -2.8%
Value US$91,000
GLOVER JAMES T Non-Executive Director
Transaction date
Purchase
Price
2.80
Quantity 10,000 +inf%
Value US$28,000
3.0
Murphy Keith Chairman, CEO and President Executive Director
Transaction date
Purchase
Price
2.56
Quantity 20,000 +0.3%
Value US$51,188
MICHAELS BARRY D Chief Financial Officer Officer
Transaction date
Planned sale
Price
7.50
Quantity 10,500 -3.5%
Value US$78,771
David Eric Chief Strategy Officer Officer
Transaction date
Planned sale
Price
7.56
Quantity 16,300 -2.3%
Value US$123,243
MICHAELS BARRY D Chief Financial Officer Officer
Transaction date
Planned sale
Price
7.50
Quantity 4,500 -1.5%
Value US$33,750
Renard Michael EVP of Commercial Operations Officer
Transaction date
Planned sale
Price
10.65
Quantity 10,000 -100.0%
Value US$106,500
Renard Michael EVP of Commercial Operations Officer
Transaction date
Planned sale
Price
9.93
Quantity 30,000 -100.0%
Value US$297,999
Renard Michael EVP of Commercial Operations Officer
Transaction date
Planned sale
Price
8.92
Quantity 10,000 -100.0%
Value US$89,200
David Eric Chief Strategy Officer Officer
Transaction date
Sale
Price
10.39
Quantity 16,470 -2.2%
Value US$171,105
Murphy Keith Chairman, CEO and President Executive Director
Transaction date
Planned sale
Price
6.63
Quantity 30,000 -0.5%
Value US$198,990
0.5
David Eric Chief Strategy Officer Officer
Transaction date
Sale
Price
5.66
Quantity 3,530 -0.5%
Value US$19,996
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-01 2026-08-31 B Purchase
Lialin Tony Serge

Chief Commercial Officer

Officer
60,828 -34.8%
160.39
US$569,548 		60,828 -34.8% 160.39 US$569,548
2023-11-17 2023-11-15 S Sale
3.3
Gobel David
Non-Executive Director
4,750 -16.7%
207.97
US$3,459,936 		4,750 -16.7% 207.97 US$3,459,936
2023-11-15 2023-11-15 PrS Proposed sale
3.3
Gobel David

Director

Non-Executive Director
15,365
392.25
US$3,933,000 		15,365 392.25 US$3,933,000
2019-08-19 2019-08-16 S Sale Hughes Steven George

Chief Medical Officer

Officer
22,230 -13.8%
0.29
US$6,431 		22,230 -13.8% 0.29 US$6,431
2018-11-13 2018-11-08 PlS Planned sale Presnell Sharon Collins

Chief Scientific Officer

Officer
40,000 -12.0%
1.27
US$50,800 		40,000 -12.0% 1.27 US$50,800
2017-12-04 2017-11-24 B Purchase Murphy Keith

Former affiliate last filing
200,500 +3.2%
1.49
US$299,346 		200,500 +3.2% 1.49 US$299,346
2017-12-04 2017-11-22 B Purchase Murphy Keith

Former affiliate last filing
135,000 +2.2%
1.50
US$201,960 		135,000 +2.2% 1.50 US$201,960
2017-02-10 2017-02-09 PlS Planned sale
3.0
Murphy Keith

Chairman, CEO and President

Executive Director
25,000 -0.4%
3.68
US$92,035 		25,000 -0.4% 3.68 US$92,035
2017-01-25 2017-01-24 PlS Planned sale
3.0
Murphy Keith

Chairman, CEO and President

Executive Director
20,100 -0.3%
3.50
US$70,440 		20,100 -0.3% 3.50 US$70,440
2017-01-25 2017-01-23 PlS Planned sale
3.0
Murphy Keith

Chairman, CEO and President

Executive Director
4,900 -0.1%
3.51
US$17,215 		4,900 -0.1% 3.51 US$17,215
2016-12-15 2016-12-14 PlS Planned sale Murphy Keith

Chairman, CEO and President

Executive Director
50,000 -0.8%
3.72
US$185,955 		50,000 -0.8% 3.72 US$185,955
2016-08-09 2016-08-05 PlS Planned sale David Eric

CSO & EVP Pre-Clinical Dev

Officer
20,000 -2.8%
4.55
US$91,000 		20,000 -2.8% 4.55 US$91,000
2015-08-13 2015-08-13 B Purchase GLOVER JAMES T Non-Executive Director
10,000 +inf%
2.80
US$28,000 		10,000 +inf% 2.80 US$28,000
2015-08-13 2015-08-12 B Purchase
3.0
Murphy Keith

Chairman, CEO and President

Executive Director
20,000 +0.3%
2.56
US$51,188 		20,000 +0.3% 2.56 US$51,188
2014-12-31 2014-12-30 PlS Planned sale MICHAELS BARRY D

Chief Financial Officer

Officer
10,500 -3.5%
7.50
US$78,771 		10,500 -3.5% 7.50 US$78,771
2014-12-31 2014-12-30 PlS Planned sale David Eric

Chief Strategy Officer

Officer
16,300 -2.3%
7.56
US$123,243 		16,300 -2.3% 7.56 US$123,243
2014-12-31 2014-12-29 PlS Planned sale
MICHAELS BARRY D

Chief Financial Officer

Officer
4,500 -1.5%
7.50
US$33,750 		4,500 -1.5% 7.50 US$33,750
2014-02-21 2014-02-21 PlS Planned sale
Renard Michael

EVP of Commercial Operations

Officer
10,000 -100.0%
10.65
US$106,500 		10,000 -100.0% 10.65 US$106,500
2014-01-29 2014-01-29 PlS Planned sale Renard Michael

EVP of Commercial Operations

Officer
30,000 -100.0%
9.93
US$297,999 		30,000 -100.0% 9.93 US$297,999
2014-01-29 2014-01-27 PlS Planned sale Renard Michael

EVP of Commercial Operations

Officer
10,000 -100.0%
8.92
US$89,200 		10,000 -100.0% 8.92 US$89,200
2013-11-15 2013-11-13 S Sale David Eric

Chief Strategy Officer

Officer
16,470 -2.2%
10.39
US$171,105 		16,470 -2.2% 10.39 US$171,105
2013-10-18 2013-10-18 PlS Planned sale Murphy Keith

Chairman, CEO and President

Executive Director
30,000 -0.5%
6.63
US$198,990 		30,000 -0.5% 6.63 US$198,990
2013-10-15 2013-10-10 S Sale
0.5
David Eric

Chief Strategy Officer

Officer
3,530 -0.5%
5.66
US$19,996 		3,530 -0.5% 5.66 US$19,996
Explore more

More insider trading research around VivoSim Labs Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America